Protocol Ledger

NCT04611152 · Phase III · TERMINATED

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

Interventional Phase III clinical trial protocol NCT04611152 sponsored by Kodiak Sciences in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-30 Enrollment: 460 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04611152
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)460 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04611152
Protocol FieldVerified Registry Value
NCT IdentifierNCT04611152
Consolidated Lead SponsorKodiak Sciences
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment460 participants (ACTUAL)
Registered Start Date2020-09-30
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04611152
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI